SEQUANA MEDICAL ANNOUNCES DECISION OF MAJOR SHAREHOLDERS TO INVEST IN SECOND TRANCHE OF CONVERTIBLE BRIDGE LOAN Ghent, Belgium, 6 December 2024 – (Euronext Brussels: SEQUA) (the "Company" or "Sequana ...
Hepatitis B virus is a viral infection which affects the liver and can result in permanent liver damage. It is currently the leading cause of chronic liver | Immunology ...
We appreciate FDA’s support in designating REVASCOR both RMAT and RPD status, a recognition of the potential impact of our therapy on the long-term adverse outcomes of these desperately ill children.